Abstract: The color-intensity of exposed and developed Kodachrome color film in the form of color transparencies or continuous strip such as movie film can be reduced by treating selected areas or all of the emulsion side of said color film with an aqueous solution of a dichromate salt acidified with an inorganic mineral acid or formic acid. Any undesirable alteration in color tone is minimized by including a soluble salt of nickel or cobalt in said aqueous solution. The reduction in color-intensity is a function of time and/or acid concentration.

Abstract: A method is disclosed for preparing an activated microporous substrate to which antibody may be covalently bonded through trichloro-triazine to yield an activated substrate which is very useful for many immunochemical reactions utilizing a flow-through procedure.

Abstract: An arterial blood sampling syringe consisting of a barrel and a plunger assembly in which the plunger is hollow and provided at its distal end with two annular rings which cooperate with the hollow plunger and each other to maintain a sealing ring and gas-pervious but liquid impervious membrane in position at the end of the plunger. The plunger position in the barrel may be preset to receive any desired blood sample volume. Further blood flow is halted when the barrel of the syringe fills to the volume desired.

Abstract: Theophylline concentrations in body fluids can be determined by a color reaction. The theophylline is converted to theophyllidine by reaction with an alkali such as sodium or potassium hydroxide at an elevated temperature and, after neutralization of the alkali with an organic acid, the theophyllidine formed is coupled with a chromogen to yield a color whose depth is proportional to the theophylline concentration in the body fluid being tested. The improved procedure utilizes a solid alkali for the heating step and a non-corrosive acid for the neutralization. An improved chromogen yields a bright, relatively stable purple color.

Abstract: The present invention relates to prostaglandin analogues of the general formula: ##STR1## [wherein A represents a grouping of the formula: ##STR2## X represents trans-vinylene or ethylene and Y represents cis-vinylene or ethylene, R represents a group of the formula --COOR.sup.4, in which R.sup.4 represents hydrogen or straight- or branched-chain alkyl of 1 to 12 carbon atoms, or a group of the formula --CH.sub.2 OR.sup.5, in which R.sup.5 represents hydrogen or alkylcarbonyl of 2 to 5 carbon atoms and R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each represent hydrogen, straight- or branched-chain alkyl of 1 to 12 carbon atoms, or an aryl group unsubstituted or substituted by one, two or three substituents selected from alkyl, alkoxy, alkylthio, monoalkylamino and dialkylamino groups and halogen atoms, the alkyl groups or moieties of the said groups containing from 1 to 5 carbon atoms in a straight- or branched-chain, with the proviso that at least one of the symbols R.sup.1, R.sup.

Abstract: Certain 4,9-dihydro-9-oxo-N-1H-tetrazol-5-yl-pyrazolo[5,1-b]quinazoline-2-carboxam ides are disclosed. These compounds prevent the allergic response in mammals.

Abstract: A heavy bodied reversible hydrocolloid dental impression material is disclosed. This material comprises agar-agar as the main component in which there is added a small amount of locust bean gum, potassium or zinc sulfate, a borate and nonionic poly(ethyleneoxide)homopolymer. This dental impression material is effective, for example, for bonding to an alginate material.

Abstract: The present invention is concerned with novel 3-hydroxy-pyrrolin-2-one derivatives and with the preparation thereof.

Abstract: Oxo-pyrido[1,2-a]thienopyrimidine compounds, salts thereof, methods of production, intermediates in their production, pharmaceutical compositions containing said compounds and methods for treating allergies using said compositions are disclosed.

Abstract: New 3-(3-methoxyphenoxy)-2-pyridinecarbonitriles, which are useful as pharmacological agents, especially as agents for the treatment of senility and reversal of amnesia, are disclosed. Other known 3-(3-substituted phenoxy)-2-pyridinecarbonitriles are disclosed having the same utility. The compounds can be produced by dehydrating the appropriately substituted oxime or displacing an alkoxy group to give the desired carbonitrile.

Abstract: The present invention is concerned with new N-substituted spirolactams and their preparation.

Abstract: A tableted form of fibrous triethylaminoethyl cellulose suitable for the removal of heparin from heparin-containing blood plasma. The tablet is composed of granular microcrystalline cellulose and fibrous triethylaminoethyl cellulose in a ratio of from about 5.4:1 to about 10:1. The triethylaminoethyl cellulose tablet, which is formulated to provide from about 5 to about 26 mg. of triethylaminoethyl cellulose per milliliter of plasma sample, is added to a heparin-containing blood plasma sample, the sample is agitated or allowed to stand for a time sufficient to permit adsorption of substantially all heparin present. The sample is then centrifuged and the remaining heparin-free plasma can be subjected to coagulation testing in order to determine the true clotting time.

Abstract: This invention relates to Compounds of formula II: ##STR1## wherein Y is formyl, carboxylic acid, acrylic acid, cyano or tetrazolo; X is hydrogen, lower alkanoyl or lower alkyl, and their non-toxic, pharmaceutically acceptable salts are disclosed. These compounds are useful in the prevention of allergic and asthamatic reactions.

Abstract: Tetrahydropyridylbutyrophenones of the following formula IX: ##STR1## wherein x is hydrogen, halogen such as fluorine, chlorine, bromine or iodine, trifluoromethyl, alkoxy, nitro, cyano, amino, lower alkyl of 1 to 6 carbons, aryl or substituted aryl; y is hydrogen or halogen; and n is 0, 1 or 2; and the non-toxic, pharmaceutically acceptable acid addition salts thereof. Tetrahydropyridylbutanols having the formula X: ##STR2## wherein x and y are as defined above, as well as their non-toxic, pharmaceutically acceptable acid addition salts, are also disclosed. The compounds of the invention having the formulas IX and X are useful as antipsychotics.

Abstract: Tetrahydropyridylbutyrophenones of the following formula I: ##STR1## wherein x is hydrogen, halogen such as fluorine, chlorine, bromine or iodine, trifluoromethyl, alkoxy, thioalkoxy, nitro, cyano, amino, lower alkyl of 1 to 6 carbons, aryl or substituted aryl; and y is hydrogen or halogen; and the non-toxic, pharmaceutically acceptable acid addition salts thereof. The compounds of the invention having the formula I are useful in the treatment of psychotic disorders such as schizophrenia.

Abstract: Prostaglandin E.sub.1 analogues of the general formula: ##STR1## [wherein Y represents ethylene or trans-vinylene, Z represents ethylene or trans-vinylene, R.sup.1 represents a hydrogen atom, an alkyl group containing from 1 to 12 carbon atoms, an aralkyl group containing from 7 to 12 carbon atoms, a cycloalkyl group containing from 4 to 7 carbon atoms and unsubstituted or substituted by at least one alkyl group containing from 1 to 6 carbon atoms, a phenyl group unsubstituted or substituted by at least one chlorine atom, trifluoromethyl group, alkyl group containing from 1 to 4 carbon atoms or phenyl group, a --C.sub.m H.sub.2m COOR.sup.5 group (wherein m represents an integer of from 1 to 12 and R.sup.5 represents a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms), a --C.sub.n H.sub.2n OR.sup.6 group (wherein R.sup.6 represents a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms and n represents an integer of from 2 to 12), or a ##STR2## group (wherein R.sup.7 and R.